News about "Small Lymphocytic Leukaemia "

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck discontinues the clinical development of nemtabrutinib and all three Phase 3 BELLWAVE trials following a benefit-risk assessment that raised concerns about the investigational BTK inhibitor.

Small Lymphocytic Leukaemia | 20/11/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members